Haizheng Pharmaceuticals has approved the listing of Grello tablets.

Guide: The company for TheGuero tablets according to the new category 4 approved by the State Drug Administration for listing, as through the consistency evaluation.
August 19, 2020, Zhejiang Haizheng Pharmaceutical Co., Ltd. received a "Drug Registration Certificate" issued by the State Drug Administration (hereinafter referred to as the "State Drug Administration").
thyroid tablets are mainly suitable for the treatment of acute coronary artery syndrome (ACS), reducing the incidence of cardiovascular death, myocardial infarction and stroke in ACS patients or patients with a history of myocardial infarction (MI).
in treatment for at least 12 months after ACS, tegrelo tablets work better than clopidogrel tablets.
company for Theguero tablets according to the new category 4 approved by the State Drug Administration for listing, as through the consistency evaluation.
for Theguero tablet original research drug Brilinta tablets (90mg) developed by AstraZene, domestic and foreign manufacturers are mainly AstraZene, Shenzhen Xinlitai Pharmaceutical Co., Ltd., Stone Pharmaceutical Group Europe Pharmaceutical Co., Ltd.
's global sales for 2019 were $191,538.28 million, including $178.60 million in China and $523,050.07 million in January-March 2020, including $545.52 million in China.
company submitted a drug registration application to the State Drug Administration on January 29, 2018 and accepted it.
, the company has invested about 28.14 million yuan in the drug research and development project.
.